Innoviva Gross Margin 2012-2026 | INVA
Current and historical gross margin for Innoviva (INVA) over the last 10 years. The current gross profit margin for Innoviva as of June 30, 2026 is %.
| Innoviva Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-06-30 | $0.44B | $0.32B | 72.34% |
| 2026-03-31 | $0.42B | $0.31B | 73.87% |
| 2025-12-31 | $0.41B | $0.31B | 74.76% |
| 2025-09-30 | $0.39B | $0.30B | 78.15% |
| 2025-06-30 | $0.37B | $0.30B | 81.13% |
| 2025-03-31 | $0.37B | $0.30B | 81.67% |
| 2024-12-31 | $0.36B | $0.30B | 82.73% |
| 2024-09-30 | $0.35B | $0.28B | 78.19% |
| 2024-06-30 | $0.33B | $0.26B | 78.79% |
| 2024-03-31 | $0.31B | $0.25B | 79.42% |
| 2023-12-31 | $0.31B | $0.25B | 79.35% |
| 2023-09-30 | $0.29B | $0.25B | 86.55% |
| 2023-06-30 | $0.29B | $0.26B | 88.97% |
| 2023-03-31 | $0.32B | $0.29B | 92.74% |
| 2022-12-31 | $0.33B | $0.32B | 96.07% |
| 2022-09-30 | $0.37B | $0.37B | 99.20% |
| 2022-06-30 | $0.40B | $0.40B | 100.00% |
| 2022-03-31 | $0.40B | $0.40B | 100.00% |
| 2021-12-31 | $0.39B | $0.39B | 100.00% |
| 2021-09-30 | $0.38B | $0.38B | 100.00% |
| 2021-06-30 | $0.37B | $0.37B | 100.00% |
| 2021-03-31 | $0.34B | $0.34B | 100.00% |
| 2020-12-31 | $0.34B | $0.34B | 100.00% |
| 2020-09-30 | $0.32B | $0.32B | 100.00% |
| 2020-06-30 | $0.30B | $0.30B | 100.00% |
| 2020-03-31 | $0.29B | $0.29B | 100.00% |
| 2019-12-31 | $0.26B | $0.26B | 100.00% |
| 2019-09-30 | $0.27B | $0.27B | 100.00% |
| 2019-06-30 | $0.26B | $0.26B | 100.00% |
| 2019-03-31 | $0.26B | $0.26B | 100.00% |
| 2018-12-31 | $0.26B | $0.26B | 100.00% |
| 2018-09-30 | $0.25B | $0.25B | 100.00% |
| 2018-06-30 | $0.24B | $0.24B | 100.00% |
| 2018-03-31 | $0.23B | $0.23B | 100.00% |
| 2017-12-31 | $0.22B | $0.22B | 100.00% |
| 2017-09-30 | $0.19B | $0.19B | 100.00% |
| 2017-06-30 | $0.18B | $0.18B | 100.00% |
| 2017-03-31 | $0.15B | $0.15B | 100.00% |
| 2016-12-31 | $0.13B | $0.13B | 100.00% |
| 2016-09-30 | $0.11B | $0.11B | 100.00% |
| 2016-06-30 | $0.09B | $0.09B | 100.00% |
| 2016-03-31 | $0.07B | $0.07B | 100.00% |
| 2015-12-31 | $0.06B | $0.06B | 100.00% |
| 2015-09-30 | $0.04B | $0.04B | 100.00% |
| 2015-06-30 | $0.03B | $0.03B | 100.00% |
| 2015-03-31 | $0.02B | $0.02B | 100.00% |
| 2014-12-31 | $0.01B | $0.01B | 100.00% |
| 2014-09-30 | $0.00B | $0.00B | 100.00% |
| 2014-06-30 | $0.00B | $0.00B | 100.00% |
| 2014-03-31 | $0.00B | $0.00B | 100.00% |
| 2013-12-31 | $0.00B | $0.00B | 100.00% |
| 2013-09-30 | $0.01B | $0.01B | 100.00% |
| 2013-06-30 | $0.01B | $0.01B | 100.00% |
| 2013-03-31 | $0.01B | $0.01B | 100.00% |
| 2012-12-31 | $0.14B | $0.14B | 100.00% |
| 2012-09-30 | $0.13B | $0.13B | 100.00% |
| 2012-06-30 | $0.14B | $0.14B | 100.00% |
| 2012-03-31 | $0.14B | $0.14B | 100.00% |
| 2011-12-31 | $0.02B | $0.02B | 100.00% |
| 2011-09-30 | $0.03B | $0.03B | 100.00% |
| 2011-06-30 | $0.02B | $0.02B | 100.00% |
| 2011-03-31 | $0.02B | $0.02B | 100.00% |
| 2010-12-31 | $0.02B | $0.02B | 100.00% |
| 2010-09-30 | $0.02B | $0.02B | 100.00% |
| 2010-06-30 | $0.02B | $0.02B | 100.00% |
| 2010-03-31 | $0.02B | $0.02B | 100.00% |
| 2009-12-31 | $0.03B | $0.03B | 100.00% |
| 2009-09-30 | $0.03B | $0.03B | 100.00% |
| 2009-06-30 | $0.03B | $0.03B | 100.00% |
| 2009-03-31 | $0.03B | $0.03B | 100.00% |
| 2008-12-31 | $0.02B | $0.02B | 100.00% |
| 2008-09-30 | $0.02B | $0.02B | 100.00% |
| 2008-06-30 | $0.02B | $0.02B | 100.00% |
| 2008-03-31 | $0.02B | $0.02B | 100.00% |
| 2007-12-31 | $0.02B | $0.02B | 100.00% |
| 2007-09-30 | $0.02B | $0.02B | 100.00% |
| 2007-06-30 | $0.02B | $0.02B | 100.00% |
| 2007-03-31 | $0.02B | $0.02B | 100.00% |
| 2006-12-31 | $0.02B | $0.02B | 100.00% |
| 2006-09-30 | $0.02B | $0.02B | 100.00% |
| 2006-06-30 | $0.02B | $0.02B | 100.00% |
| 2006-03-31 | $0.01B | $0.01B | 100.00% |
| 2005-12-31 | $0.01B | $0.01B | 100.00% |
| 2005-09-30 | $0.01B | $0.01B | 100.00% |
| 2005-06-30 | $0.01B | $0.01B | 100.00% |
| 2005-03-31 | $0.01B | $0.01B | 100.00% |
| 2004-12-31 | $0.01B | $0.01B | 100.00% |
| 2004-09-30 | $0.01B | $0.01B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.510B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |